Effects of mitomycin C on the oxygenation and radiosensitivity of murine and human tumours in mice

Radiotherapy and Oncology

Volumn 56, Issue 2, 2000, Pages 245-252

  Durand, Ralph E ^a   Lepard, Nancy E ^a  

^a BRITISH COLUMBIA CANCER RESEARCH CENTRE   (Canada)

Author keywords

Bioreductive drugs; Cell sorting; Combined modalities; Dye mismatch; Laser Doppler; Tumour blood flow

Indexed keywords

MITOMYCIN C;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; CANCER; CONTROLLED STUDY; CYTOTOXICITY; DOPPLER FLOWMETRY; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; OXYGENATION; PRIORITY JOURNAL; RADIOSENSITIZATION; TUMOR BLOOD FLOW; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; APOPTOSIS; CERVIX UTERI; COLON; COLONIC NEOPLASMS; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; LASER-DOPPLER FLOWMETRY; MALE; MICE; MICE, NUDE; MICE, SCID; MITOMYCIN; OXYGEN CONSUMPTION; RADIATION TOLERANCE; REGIONAL BLOOD FLOW; SPECIES SPECIFICITY; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED; UTERINE CERVICAL NEOPLASMS;

EID: 0034254171     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-8140(00)00180-8     Document Type: Article

References (38)

1. Adams G.E., Stratford I.J. Bioreductive drugs for cancer therapy: the search for tumour specificity. Int. J. Radiat. Oncol. Biol. Phys. 29:1994;231-238.
2. Brown J.M. SR 4233 (tirapazamine): a new anticancer drug exploiting hypoxia in solid tumours. Br. J. Cancer. 67:1993;1163-1170.
3. Brown J.M., Giaccia A.J. Tumour hypoxia: the picture has changed in the 1990s. Int. J. Radiat. Biol. 65:1994;95-102.
4. Bush R.S., Jenkin R.D.T., Allt W.E.C., et al. Definitive evidence for hypoxic cells influencing cure in cancer therapy. Br. J. Cancer. 37:1978;302-306.
5. Chaplin D.J., Durand R.E., Olive P.L. Cell selection from a murine tumour using the fluorescent probe Hoechst 33342. Br. J. Cancer. 51:1985;569-572.
6. Chaplin D.J., Trotter M.J., Durand R.E., Olive P.L., Minchinton A.I. Evidence for intermittent radiobiological hypoxia in experimental tumour systems. Biomed. Biochim. Acta. 48:1989;255-259.
7. Dische S. Hyperbaric oxygen: The Medical Research Council trials and their clinical significance. Br. J. Radiol. 51:1979;888-894.
8. Durand R.E. Use of a cell sorter for assays of cell clonogenicity. Cancer Res. 46:1986;2775-2778.
9. Durand R.E. Synergism of cisplatin and mitomycin C in sensitive and resistant cell subpopulations of a tumor model. Int. J. Cancer. 44:1989;911-917.
10. Durand R.E. The influence of microenvironmental factors on the activity of radiation and drugs. Int. J. Radiat. Oncol. Biol. Phys. 20:1991;253-258.
11. Durand R.E. The influence of microenvironmental factors during cancer therapy. In Vivo. 8:1994;691-702.
12. Durand R.E., LePard N.E. Modulation of tumor hypoxia by conventional chemotherapeutic agents. Int. J. Radiat. Oncol. Biol. Phys. 29:1994;481-486.
13. Durand R.E., LePard N.E. Contribution of transient blood flow to tumour hypoxia in mice. Acta Oncol. 34:1995;317-324.
14. Durand R.E., LePard N.E. Tumour blood flow influences combined radiation and doxorubicin treatments. Radiother. Oncol. 42:1997;171-179.
15. Durand R.E., Olive P.L. Evaluation of bioreductive drugs in multicell spheroids. Int. J. Radiat. Oncol. Biol. Phys. 22:1992;689-692.
16. Durand R.E., Olive P.L. Physiologic and cytotoxic effects of tirapazamine in tumor-bearing mice. Radiat. Oncol. Invest. 5:1997;213-219.
17. Durand R.E., Raleigh J.A. Identification of nonproliferating but viable hypoxic tumor cells in vivo. Cancer Res. 58:1998;3547-3550.
18. Durand R.E., Vanderbyl S.L. Response of cell subpopulations in spheroids to radiation-drug combinations. N.C.I. Monogr. 6:1988;95-100.
19. Friedl F., Kimura I., Osato T., Ito Y. Studies on a new human cell line (SiHa) derived from carcinoma of uterus. I. Its establishment and morphology. Proc. Soc. Expt. Biol. Med. 135:1970;543-545.
20. Gatenby R.A., Kessler H.B., Rosenblum J.S., et al. Oxygen distribution in squamous cell carcinoma metastases and its relationship to outcome of radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 14:1988;831-838.
21. 2 gradients in solid tumors in vivo: high-resolution measurements reveal a lack of correlation. Nat. Med. 3:1997;177-182.
22. Hockel M., Schlenger K., Aral B., Mitze M., Schaffer U., Vaupel P. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res. 56:1996;4509-4515.
23. Huang P., Olive P.L., Durand R.E. Use of the comet assay for assessment of drug resistance and its modulation in vivo. Br. J. Cancer. 77:1998;412-416.
24. Jain R.K. Therapeutic implications of tumor physiology. Curr. Opin. Oncol. 3:1991;1105-1108.
25. Marshall R.S., Paterson M.C., Rauth A.M. Deficient activation by a human cell strain leads to mitomycin resistance under aerobic but not hypoxic conditions. Br. J. Cancer. 59:1989;341-346.
26. Noguchi P., Wallace R., Johnson J., et al. Characterization of the WIDR: a human colon carcinoma cell line. In Vitro. 15:1979;401-408.
27. Olive P.L., Chaplin D.J., Durand R.E. Pharmacokinetics, binding and distribution of Hoechst 33342 in spheroids and murine tumours. Br. J. Cancer. 52:1985;739-746.
28. Rockwell S. Cytotoxicities of mitomycin C and X-rays to aerobic and hypoxic cells in vitro. Int. J. Radiat. Oncol. Biol. Phys. 8:1982;1035-1039.
29. Rockwell S. Hypoxic cells as targets for cancer chemotherapy. Cheng Y.C., Goz B., Minkoff M. The development of target oriented anticancer drugs. 1983;157-172 Raven Press, New York.
30. Sartorelli A.C. Therapeutic attack of hypoxic cells of solid tumors: Presidential address. Cancer Res. 48:1988;775-778.
31. Sham E., Durand R.E. Repopulation characteristics and cell kinetic parameters resulting from multifraction irradiation of xenograft tumors in SCID mice. Int. J. Radiat. Oncol. Biol. Phys. 43:1999;617-622.
32. Shepherd A.P., Riedel G.L., Kiel J.W., Haumschild D.J., Maxwell L.C. Evaluation of an infrared laser-Doppler blood flowmeter. Am. J. Physiol. 252:1987;G832-G839.
33. Sutherland R.M. Cell and environment interactions in tumor microregions: the multicell spheroid model. Science. 240:1988;177-184.
34. Trotter M.J., Chaplin D.J., Durand R.E., Olive P.L. The use of fluorescent probes to identify regions of transient perfusion in murine tumors. Int. J. Radiat. Oncol. Biol. Phys. 16:1989;931-934.
35. Walton M.I., Wolf C.R., Workman P. Molecular enzymology of the reductive bioactivation of hypoxic cell cytotoxins. Int. J. Radiat. Oncol. Biol. Phys. 16:1989;983-986.
36. Weissberg J.B., Son Y.H., Papac R.J., et al. Randomized clinical trial of mitomycin C as an adjunct to radiotherapy in head and neck cancer. Int. J. Radiat. Oncol. Biol. Phys. 17:1989;3-9.
37. Workman P. Bioreductive mechanisms. Int. J. Radiat. Oncol. Biol. Phys. 22:1992;631-637.
38. Yan R., Durand R.E. The response of hypoxic cells in SCCVII murine tumors to treatment with cisplatin and X-rays. Int. J. Radiat. Oncol. Biol. Phys. 20:1991;271-274.